argenx stock

ARGX · NASDAQ · USD

$960.04Change from previous close: −2.17%Absolute change: −$21.29

Close · November 13, 2026

Price history

+7.66% over the period

1 year: from $891.73 (November 13, 2025) to $960.04 (November 13, 2026), +7.66%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$960.04
October 30, 2026$892.87
September 30, 2026$958.91
August 31, 2026$1,031.66
July 31, 2026$853.82
June 30, 2026$927.77
May 29, 2026$835.99
April 30, 2026$781.72
March 31, 2026$730.25
February 27, 2026$766.92
January 30, 2026$840.50
December 31, 2025$840.95
November 28, 2025$911.98
November 13, 2025$891.73

At a glance

  • The company

    Commercial-stage biopharma company developing therapies for autoimmune diseases including VYVGART and VYVGART HYTRULO

  • Latest results

    Quarter to September 30, 2026 · EPS $7.80 (estimate $7.67)

TickerLandia's take on argenx

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$661.85
52-wk high$1,072.75

−10.51% from the 52-week high

Analysts · 25 analysts

Average target$1,144.74+19.24% vs. price

Buy 22 · Hold 3 · Sell 0 · Buy

TickerLandia Fingerprint: argenx

Compared with similar companies: very high financial strength and very high growth.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

argenx is in line with similar companies

argenx's P/E (trailing 12 months): 33.3, in line with the median of a group of 7 similar companies (34.7).

Compared with 7 similar companies

argenx's metrics compared with similar companies
MetricargenxPosition in the groupBand
P/E (trailing 12 months)33.3Middle
Forward P/E28.8Middle
Operating margin31.9%Middle
ROE23.6%High
Debt/equity0.01Low

Grey band: the middle half of the group; tick: the median; dot: argenx. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.75B

Latest quarter · Q3 2026

Net income

$506M

Latest quarter · Q3 2026

Quarterly net margin

28.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$60.37B
P/E
33.3
EPS
$28.87
Volume
225.89K
Daily trading
€337.3M
Dividend yield
0.00%

How argenx is changing

All results
  • Revenue grew 152.5% a year on average over the last 5 years

  • Operating margin rose from −7,184.7% to 24.9%

  • Less cash than profit: free cash flow equal to 9% of net income

Returns

argenx returns

$1,000 invested in argenx 5 years ago, on November 15, 2021, would be worth $3,187 today: +218.74% in total, +26.13% per year. This is the price return only: dividends are excluded.

PeriodargenxS&P 500$1,000 becomes
1 month+19.61%−3.12%$1,196
6 months+19.60%+1.58%$1,196
Year to date+14.16%+10.46%$1,142
1 year+7.66%+12.23%$1,077
3 years+95.87%+71.41%$1,959
5 years+218.74%+61.48%$3,187

Over the last 6 months it has done better than 54% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

argenx: technical analysis

argenx is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 9.3% below its all-time closing high ($1,058.90, August 27, 2026).

Trend
Upward
RSI (14 sessions)
59
Between 30 and 70
vs 200-session average
+11.60%

Support and resistance

Price areas where argenx has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$960.04
  3. Support$934.56−2.65%5 touches, last on September 23, 2026
  4. Support$887.39−7.57%3 touches, last on August 7, 2026
  5. Support$855.61−10.88%3 touches, last on April 17, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.53
Volatility (60 sessions, annualised)
40.4%
Largest fall in the last year
−28.58%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

argenx: seasonality

Average monthly price change over 10 years

+0.8%Jan+2.7%Feb−2.2%Mar+3.7%Apr+6.1%May+5.9%Jun+7.0%Jul+3.7%Aug−2.7%Sep+2.6%Oct+11.6%Nov+11.6%Dec

Over the last 10 years, the strongest month for argenx has been November: +11.64% on average, positive in 7 years out of 9. The weakest has been September: −2.70% on average, positive in 4 years out of 10.

Show chart data
MonthAverageMedianPositive years
January+0.79%+0.02%5 of 9
February+2.70%−1.22%3 of 9
March−2.22%−4.78%4 of 9
April+3.72%+4.11%7 of 9
May+6.11%+0.21%5 of 9
June+5.94%+5.31%8 of 10
July+7.01%+1.65%6 of 10
August+3.66%+1.94%7 of 10
September−2.70%−4.36%4 of 10
October+2.65%+3.43%6 of 10
November+11.64%+11.42%7 of 9
December+11.60%−0.25%4 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

argenx and its competitors

With revenue of $4.2 billion, argenx SE is a commercial-stage biopharmaceutical company that develops therapies for autoimmune diseases. It offers VYVGART for generalized myasthenia gravis and immune thrombocytopenia, and VYVGART HYTRULO for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Its development programs cover a range of other autoimmune conditions, and it has partnerships and license agreements with Zai Lab, Halozyme Therapeutics, OncoVerity and AbbVie. The United States accounted for 83.2% of revenue, with the remainder coming from Japan, China and the rest of the world.

Headquarters
Amsterdam, Netherlands
Employees
1,863
Founded
2008
Chief executive
Karen Massey
argenx and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
argenxARGX$60.37B31.9%33.3+19.60%
BeOne MedicinesONC$47.58B17.8%53.4+31.59%
ModernaMRNA$90.38B-80.8%—+343.02%
Royalty PharmaRPRX$39.85B64.4%45.3+30.16%
Revolution MedicinesRVMD$37.27B-853.0%—+14.91%
Regeneron PharmaceuticalsREGN$98.84B30.4%21.1+32.73%

Same industry or related industries, similar size. Compare argenx with its competitors · Full profile